Rigosertib
Rigosertib is a multi-kinase inhibitor and selective anticancer compound that induces cell apoptosis by inhibiting PI3K/Akt pathway, promoting phosphorylation of histone H2AX and inducing G2/M phase arrest in the cell cycle. Rigosertib is a selective non-ATP-competitive PLK1 inhibitor.